Biocorrx (OTCMKTS:BICX – Get Free Report) and GoodRx (NASDAQ:GDRX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Profitability
This table compares Biocorrx and GoodRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biocorrx | N/A | N/A | -96.39% |
| GoodRx | 3.82% | 9.31% | 4.38% |
Insider and Institutional Ownership
63.8% of GoodRx shares are owned by institutional investors. 21.4% of Biocorrx shares are owned by insiders. Comparatively, 4.2% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biocorrx | $10,000.00 | 1,056.00 | -$5.11 million | ($0.32) | -1.25 |
| GoodRx | $796.85 million | 0.87 | $30.44 million | $0.09 | 22.56 |
GoodRx has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Biocorrx and GoodRx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biocorrx | 0 | 1 | 0 | 0 | 2.00 |
| GoodRx | 3 | 8 | 5 | 0 | 2.13 |
GoodRx has a consensus price target of $3.98, suggesting a potential upside of 96.10%. Given GoodRx’s stronger consensus rating and higher possible upside, analysts plainly believe GoodRx is more favorable than Biocorrx.
Risk & Volatility
Biocorrx has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
Summary
GoodRx beats Biocorrx on 12 of the 14 factors compared between the two stocks.
About Biocorrx
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
About GoodRx
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
